Azrak RG - Search Results

1

A phase I and pharmacokinetic study of fixed-dose selenomethionine and irinotecan in solid tumors.

Fakih MG, Pendyala L, Smith PF, Creaven PJ, Reid ME, Badmaev V, Azrak RG, Prey JD, Lawrence D, Rustum YM. Fakih MG, et al. Among authors: azrak rg. Clin Cancer Res. 2006 Feb 15;12(4):1237-44. doi: 10.1158/1078-0432.CCR-05-2004. Clin Cancer Res. 2006. PMID: 16489079 Clinical Trial.

2

Lack of microvessels in well-differentiated regions of human head and neck squamous cell carcinoma A253 associated with functional magnetic resonance imaging detectable hypoxia, limited drug delivery, and resistance to irinotecan therapy.

Bhattacharya A, Tóth K, Mazurchuk R, Spernyak JA, Slocum HK, Pendyala L, Azrak R, Cao S, Durrani FA, Rustum YM. Bhattacharya A, et al. Clin Cancer Res. 2004 Dec 1;10(23):8005-17. doi: 10.1158/1078-0432.CCR-04-1306. Clin Cancer Res. 2004. PMID: 15585636

3

Therapeutic synergy between irinotecan and 5-fluorouracil against human tumor xenografts.

Azrak RG, Cao S, Slocum HK, Tóth K, Durrani FA, Yin MB, Pendyala L, Zhang W, McLeod HL, Rustum YM. Azrak RG, et al. Clin Cancer Res. 2004 Feb 1;10(3):1121-9. doi: 10.1158/1078-0432.ccr-0913-3. Clin Cancer Res. 2004. PMID: 14871992

4

Irinotecan pharmacokinetic and pharmacogenomic alterations induced by methylselenocysteine in human head and neck xenograft tumors.

Azrak RG, Yu J, Pendyala L, Smith PF, Cao S, Li X, Shannon WD, Durrani FA, McLeod HL, Rustum YM. Azrak RG, et al. Mol Cancer Ther. 2005 May;4(5):843-54. doi: 10.1158/1535-7163.MCT-04-0315. Mol Cancer Ther. 2005. PMID: 15897249

5

Efficacy of increasing the therapeutic index of irinotecan, plasma and tissue selenium concentrations is methylselenocysteine dose dependent.

Azrak RG, Cao S, Pendyala L, Durrani FA, Fakih M, Combs GF Jr, Prey J, Smith PF, Rustum YM. Azrak RG, et al. Biochem Pharmacol. 2007 May 1;73(9):1280-7. doi: 10.1016/j.bcp.2006.12.020. Epub 2006 Dec 22. Biochem Pharmacol. 2007. PMID: 17239826 Free PMC article.

6

Augmented therapeutic efficacy of irinotecan is associated with enhanced drug accumulation.

Azrak RG, Cao S, Durrani FA, Toth K, Bhattacharya A, Rustum YM. Azrak RG, et al. Cancer Lett. 2011 Dec 8;311(2):219-29. doi: 10.1016/j.canlet.2011.07.023. Epub 2011 Aug 6. Cancer Lett. 2011. PMID: 21872389 Free PMC article.

7

Overexpression of Bax enhances antitumor activity of chemotherapeutic agents in human head and neck squamous cell carcinoma.

Guo B, Cao S, Tóth K, Azrak RG, Rustum YM. Guo B, et al. Among authors: azrak rg. Clin Cancer Res. 2000 Feb;6(2):718-24. Clin Cancer Res. 2000. PMID: 10690558

8

Targeting the oncogenic protein beta-catenin to enhance chemotherapy outcome against solid human cancers.

Saifo MS, Rempinski DR Jr, Rustum YM, Azrak RG. Saifo MS, et al. Among authors: azrak rg. Mol Cancer. 2010 Dec 2;9:310. doi: 10.1186/1476-4598-9-310. Mol Cancer. 2010. PMID: 21126356 Free PMC article.

9

Enhanced 7-ethyl-10-hydroxycamptothecin (SN-38) lethality by methylselenocysteine is associated with Chk2 phosphorylation at threonine-68 and down-regulation of Cdc6 expression.

Yin MB, Li ZR, Cao S, Durrani FA, Azrak RG, Frank C, Rustum YM. Yin MB, et al. Among authors: azrak rg. Mol Pharmacol. 2004 Jul;66(1):153-60. doi: 10.1124/mol.66.1.153. Mol Pharmacol. 2004. Retraction in: Mol Pharmacol. 2006 Mar;69(3):1074. PMID: 15213307 Retracted.

10

Silencing survivin results in synergy between methylseleninic acid and paclitaxel against skov3 ovarian cancer cells.

Azrak RG, Frank CL, Ghadersohi A, Rustum YM. Azrak RG, et al. Cancer Biol Ther. 2008 Dec;7(12):1901-8. doi: 10.4161/cbt.7.12.6939. Epub 2008 Dec 7. Cancer Biol Ther. 2008. PMID: 18981709 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

19 results

Search Page

Filters